Trial Profile

A Phase 1 Study of LY3127804 as Monotherapy and in Combination With Ramucirumab in Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ramucirumab (Primary) ; Zansecimab (Primary) ; Paclitaxel
Indications Adenocarcinoma; Carcinoma; Cervical cancer; Endometrial cancer; Gastric cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Acronyms JQBA
Sponsors Eli Lilly and Company

Most Recent Events

16 Oct 2020 Status changed from active, no longer recruiting to completed.
03 Aug 2020 Results (n=62) determining the RP2D and schedule of LY3127804 as monotherapy and combination with ramucirumabpublished in the British Journal of Cancer
04 May 2020 Planned End Date changed from 22 May 2020 to 20 Nov 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com